Protective Effect of N-acetylcysteine on Oxaliplatin-Induced Neuropathy in Colorectal Cancer

Inclusion Criteria:

* Males and females aged ≥ 18 years old.
* Patients with histologically confirmed diagnosis of Stage III colorectal cancer and high risk Stage II.
* Patients who will be scheduled to receive modified FOLFOX-6.
* Patients with no contraindication to chemotherapy.
* Adequate baseline hematologic values (absolute neutrophilic count ≥ 1.5

  * 109/L, platelet count ≥ 100 × 109/L and hemoglobin level ≥ 10 g/dl).
* Patients with adequate renal function (serum creatinine \< 1.5 mg/dl or creatinine clearance (ClCr) ˃ 45 mL/min).
* Patients with adequate liver function (serum bilirubin \< 1.5 mg/dl).
* Patients with performance status 0-1 according to Eastern Cooperative Oncology Group (ECOG) score.

Exclusion Criteria:

* Children \< 18 years old.
* Prior exposure to chemotherapy.
* Patients with diabetes and other conditions that predispose to neuropathy.
* History of known allergy to oxaliplatin or other platinum agents.
* Concomitant use of any drug has anti-oxidant activity or neuroprotective agent.
* Patients take any medication that increase acetyle choline either central or peripheral.
* Patient was any cardiac disease.
* Pregnant and breastfeeding women.